title: [Incretin-based therapy for treating patients with type 2 diabetes].
abstract: In the last couple of years, a new class of antidiabetic drugs became available for the clinical practice. Due to the intensive research, several new drugs reached the market. Among the incretinmimetics both the GLP-1 (glucagon like peptide-1)-receptor agonist exenatide and the GLP-1-analogue liraglutide can be used for treatment. As for incretin enhancers (dipeptidyl-peptidase-4 [DPP-4]-inhibitors), sitagliptin, vildagliptin and saxagliptin are available in Hungary, linagliptin will be introduced to the market in the near future. In clinical practice, any incretin-based new drugs can be used for treating patients with type 2 diabetes, preferably in combination with metformin. The clinical experiences with these new drugs are reviewed focusing on both the benefits and the potential side-effects of the particular compounds.
authors.affiliation: Fővárosi Bajcsy-Zsilinszky Kórház III. Belgyógyászati Osztály Budapest Maglódi. gyjermendy@mail.datanet.hu
authors.forename: György
authors.initials: G
authors.lastname: Jermendy
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism*; D004151:Dipeptides / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D017277:Drug Approval; D004359:Drug Therapy, Combination; D000077270:Exenatide; D005907:Gliclazide / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006814:Hungary; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D054795:Incretins / Q000819:agonists* / Q000378:metabolism; D000069476:Linagliptin; D000069450:Liraglutide; D008687:Metformin / Q000627:therapeutic use; D009570:Nitriles / Q000627:therapeutic use; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D000077205:Pioglitazone; D011687:Purines / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists*; D000068900:Sitagliptin Phosphate; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use; D000077597:Vildagliptin
chemical_list: D000218:Adamantane; D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D000077270:Exenatide; D005907:Gliclazide; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins; D000069476:Linagliptin; D000069450:Liraglutide; D008687:Metformin; D009570:Nitriles; D010455:Peptides; D000077205:Pioglitazone; D011687:Purines; D011719:Pyrazines; D011759:Pyrrolidines; D011799:Quinazolines; D018027:Receptors, Glucagon; D000068900:Sitagliptin Phosphate; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D014230:Triazoles; D014688:Venoms; D000077597:Vildagliptin; C000593833:GLP1R protein, human; C517652:hemoglobin A1c protein, human; C057619:glimepiride; C502994:saxagliptin